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OBJECTIVE — This trial tested whether mycophenolate mofetil (MMF) alone or with dacli-
zumab (DZB) could arrest the loss of insulin-producing -cells in subjects with new-onset type
1 diabetes.
RESEARCH DESIGN AND METHODS — A multi-center, randomized, placebo-
controlled, double-masked trial was initiated by Type 1 Diabetes TrialNet at 13 sites in North
America and Europe. Subjects diagnosed with type 1 diabetes and with sufﬁcient C-peptide
within3monthsofdiagnosiswererandomizedtoeitherMMFalone,MMFplusDZB,orplacebo,
and then followed for 2 years. The primary outcome was the geometric mean area under the
curve (AUC) C-peptide from the 2-h mixed meal tolerance test.
RESULTS — One hundred and twenty-six subjects were randomized and treated during the
trial. The geometric mean C-peptide AUC at 2 years was unaffected by MMF alone or MMF plus
DZB versus placebo. Adverse events were more frequent in the active therapy groups relative to
the control group, but not signiﬁcantly.
CONCLUSIONS — NeitherMMFalonenorMMFincombinationwithDZBhadaneffecton
the loss of C-peptide in subjects with new-onset type 1 diabetes. Higher doses or more targeted
immunotherapies may be needed to affect the autoimmune process.
Diabetes Care 33:826–832, 2010
T
ype 1 diabetes is a chronic, slowly
progressive autoimmune disease
(1). Immunotherapy aimed at mod-
ifyingthecourseofdiseasehasbeendem-
onstrated to be successful in a number of
immune conditions including rheuma-
toid arthritis, systemic lupus erythemato-
sus, and multiple sclerosis. Infusion of an
anti-CD3 monoclonal antibody showed
preservation of -cell function in type 1
diabetes (2–4).
The Diabetes Control and Complica-
tionsTrial(DCCT)demonstratedthatim-
provedmetaboliccontrolreduceschronic
complications in type 1 diabetes (5). A
post hoc analysis of DCCT found that
those with residual -cell function, man-
ifested by C-peptide values 0.2 pmol/
ml,hadbothlesshypoglycemiaandfewer
complications than those without resid-
ual function (6). Thus an intervention
that prolongs -cell function would be
expected to improve metabolic control
and reduce complications (7).
Mycophenolic acid (MPA) was dis-
covered in 1896 and characterized in
1952. Mycophenolate mofetil (MMF) is
rapidlyabsorbedafteroraladministration
and hydrolyzed to MPA (8). MPA is a po-
tent, selective, noncompetitive, reversible
inhibitor of inosine monophosphate de-
hydrogenase that inhibits de novo
guanosine nucleotide synthesis without
incorporation into DNA. T- and B-
lymphocytes depend on de novo synthe-
sisofpurinesfortheirproliferation,while
other cell types can use salvage pathways.
Thus, MMF has potent cytostatic effects
on lymphocytes. MMF is effective in au-
toimmune diseases (psoriasis and uveitis)
(9,10), as anti-rejection therapy in trans-
plant recipients (11), and in diabetic ani-
mal models (12,13).
Daclizumab (DZB) is a humanized
monoclonalantibodythatbindstoCD25,
the  subunit of the interleukin-2 (IL-2)
receptor expressed on the surface of acti-
vated lymphocytes. DZB inhibits IL-2
binding and the progression of T-
lymphocytes through the cell cycle. The
Edmonton protocol used DZB induction
therapy in islet transplantation in type 1
diabetes (14). It has been used in several
autoimmune conditions (multiple sclero-
sis and uveitis) (15,16). Recent work in
the DR-BB rat model demonstrated a syn-
ergistic effect of these two drugs when
used together (17).
The objective of this study was to de-
termine whether MMF alone or MMF
combined with DZB could diminish pro-
gression of -cell destruction in recent-
onset type 1 diabetes.
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METHODS— This multi-center trial
was conducted at 13 sites with subjects
aged8–45yearswithautoimmunetype1
diabetes for less than 3 months and with
evidence of -cell function evidenced by
stimulatedC-peptide0.2pmolona2-h
mixedmealtolerancetest(MMTT).Auto-
immune type 1 diabetes was deﬁned by
the presence of any of four islet autoanti-
bodies within 14 days of diagnosis (GAD,
insulinoma-associated protein 2, or islet
cellautoantibodies[ICAs]).Subjectswere
otherwisehealthywithoutmajorsystemic
illness nor allergic or autoimmune condi-
tions requiring treatment with immuno-
suppressive agents or steroids. The
protocol was approved by the Type 1 Di-
abetes TrialNet Steering Committee, the
Data and Safety Monitoring Board
(DSMB), and regulatory authorities; hu-
man subject approval was obtained at
participating sites prior to study initia-
tion. All subjects provided written, in-
formed consent.
Study design
The study was a three-arm, randomized,
double-masked, placebo-controlled clin-
ical trial conducted by Type 1 Diabetes
TrialNet. Roche Pharmaceuticals pro-
vided MMF, DZB, and placebo, but had
no involvement in study management,
data collection and analysis, or manu-
script preparation. There were 126 sub-
jects randomized to receive MMF alone
(with DZB placebo), MMF and DZB in
combination, or control (MMF placebo
and DZB placebo), stratiﬁed within clini-
cal center.
By error, among the last six sites to
join the study, 12 subjects assigned to re-
ceive MMF alone inadvertently received
DZB-alone,thusresultinginanimbalance
in the group sample sizes. The results





imum 2,000 mg/day) in 2–3 divided
doses for 2 years. DZB or matched pla-
cebo was given by intravenous infusion at
study day 0 and two weeks later at a dose
of 1 mg/kg. All subjects were to be fol-
lowed for at least 2 years under the inten-
tion-to-treat principle, including those
who did not receive the full course of as-
signed therapy.
Because both drugs reduce the ability
to ﬁght viral infections, screening for cy-
tomegalovirus (CMV), and Epstein-Barr
virus (EBV) was based on close surveil-
lance rather than active prophylaxis.
Study visits were conducted to assess
safety weekly  4, biweekly  2. There-
after, EBV-negative subjects were fol-
lowed monthly, and EBV-positive
subjects were followed at 3-month inter-
vals. Visits included assessment of diabe-
tes care, adverse events, and laboratory
measurements to assess medication side
effects. In the case of an acute infection,
additional studies were performed.
All participants received intensive di-
abetesmanagementwiththegoalofmain-
taining A1C levels 7.0%.
An independent DSMB met every 6
months and had quarterly summary
safety reviews. A medical monitor,
masked to treatment assignment, re-
viewed all adverse events. An infectious
disease committee developed treatment
algorithms for common infections and
provided consultation as needed.
Laboratory assessments
Blood samples were analyzed at core lab-
oratories. A 4-h MMTT was conducted at
baseline and 2 years, and a 2-h MMTT at
3, 6, 12, and 18 months with timed sam-
ple collection at 15–30 min intervals. C-
peptidelevelsweremeasuredusingatwo-
site immunoenzymometeric assay (Tosoh
600IIanalyzer).A1Cwasmeasuredquar-
terly using ion-exchange high perfor-
manceliquidchromatography(VariantII,
Bio-RadDiagnostics).Thereliabilitycoef-
ﬁcient for each assay was 0.99 from
split duplicate samples.
Biochemical autoantibodies (GAD-
65, ICA-512, mIAA) were measured us-
ing radio-immunobinding assays; ICAs
were measured using indirect immuno-
ﬂuorescence. Potential participants were
screened for antibodies to hepatitis B sur-
face antigen, hepatitis C, and human im-
munodeﬁciency virus using enzyme
immunoassaysthat,ifpositive,resultedin
exclusion from the study.
Antibodies to CMV EBV were mea-
suredusingindirectimmunoﬂuorescence
(anti-EBV VCA IgM) and enzyme immu-
noassay (anti-CMV IgG and IgM; anti-
EBV VCA and EBNA IgG). CMV and EBV
viral load was measured using real time
quantitative PCR (Lightcycler System;
Roche Applied Science). MMF peak and
trough levels were determined by MPA
concentrations using HPLC. Flow cytom-
etry was used to measured T-lymphocyte
subpopulations, including CD4CD25.
Statistics
The prespeciﬁed primary analyses were
based on the intention-to-treat cohort
that included all subjects randomized
correctly to the three speciﬁed treat-
ment groups. The primary outcome was
the geometric mean difference between
active- and placebo-treated subjects of
the area under the stimulated C-peptide
curve over the ﬁrst2ho fa4 - hM M T T
conducted at the 2-year visit in an
ANCOVA model adjusting for the baseline
C-peptide, age, and sex. The 2-h C-
peptide area under the curve (AUC)
(pmol/ml/120 min) was computed us-
ing the trapezoidal rule from timed
measurementsofC-peptideduringeach
MMTT (including the basal). The AUC
mean (pmol/ml) equals the AUC di-
vided by the interval of time. The log-
([mean C-peptide]  1) transformation
of the baseline and follow-up AUC
mean was used to allow for mean C-
peptide values close to zero and to nor-
malize the distribution of the residuals
(6).
Data from all 13 centers contributed
to the primary and secondary effective-
ness analyses of the MMF plus DZB com-
bination and its respective control group.
However, owing to the randomization er-
ror, subjects received MMF alone in only
seven centers. Thus, these analyses com-
pare the MMF alone subjects only with
the concurrently randomized control
subjects from these centers.
Secondary analyses include assess-
ment of differences between groups over
time in a longitudinal normal errors re-
peated-measures model of the log([mean
C-peptide]  1) values. The group geo-
metric mean C–peptide was obtained us-
ing the inverse transformation. The mean
rate of change over 3–24 months was es-
timated using a mixed effects random co-
efﬁcient model (18) using the log values.
The Cox proportional hazards model as-
sessed the relative risk (hazard ratio) of
the loss of the 2-h C-peptide 0.2
pmol/ml (19).
Prespeciﬁedsecondaryoutcomesalso
include: differences in A1C, insulin dose,
hypoglycemicepisodes,ratesofinfection,
and adverse events over time.
For assessment of safety, the two ac-
tive groups are compared with the total
control group enrolled. The percents of
subjects with an event were compared
among the three groups using Fisher ex-
act test. The rate of events per subject was
comparedbetweengroupsusingthePois-
son model test (20).
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(40 per group) provided 85% power to
detect a 65% difference in the geometric
mean C-peptide for any one of the three
possiblepairwisecomparisonsamongthe
three treatment groups using a test at
the 0.05 level (one-sided, adjusted for three
comparisons), with 10% loss to follow-
up. Owing to the randomization error,
the protocol was modiﬁed to compare
the MMF and DZB combination group
versus all placebo subjects, and to com-
pare the MMF only subjects versus the
placebo subjects enrolled within the
same clinical centers (7 of the original
13) in which the randomization was not
affected, each using a test at the 0.025
level (one-sided, adjusted for two com-
parisons). The MMF plus DZB versus
placebo comparison, with about 40 per
group, provided 85% power to detect a
61%difference;andtheMMFalonever-
sus placebo comparison, with about 30
per group, provided 80% power to de-
tect a 67% increase, each allowing for
10% losses to follow-up.
In April 2008, based on 41 and 47%
of the planned total information, the
DSMB recommended termination of the
treatment phase of the study. At that time
the conditional power of each compari-
son under the current trend in the data
were less than 0.02% and under the orig-
inal design assumptions, termination for
futilityledtolessthana1%increaseinthe
probability of a type II error (21). Sites
werenotiﬁedonApril30,2008,toimme-
diately terminate treatment but continue
to follow all subjects. This report is based
on closed and locked data for all visits
through April 30, 2008. Nominal one-
sided P values (without adjustment for
multiple tests) are presented for analyses
of primary and secondary effectiveness




Supplemental Figure A1 (available in
the online appendix at http://care.
diabetesjournals.org/cgi/content/full/dc09-
1349) summarizes subject disposition-
screening of 228 subjects, randomization
of 126 subjects, and subsequent disposi-
tion. Table 1 presents baseline character-
istics for each active therapy group versus
its respective control group. The groups
were well-matched with 30% ages 8–12
years, 31% ages 13–17 years, and 39%
age 18 years. Mean time from diagnosis
to enrollment was 76 days.
Safety data are presented on all 114
properly randomized subjects, excluding
the 12 who received the DZB-alone in-
stead of MMF alone. Of these, 60 com-
pleted an MMTT at 2 years and
contributed to the primary outcome
analysis.
All randomized subjects received
study treatment, and all but one received
the two planned DZB/placebo infusions.
Median compliance with MMF daily cap-
suleswasestimatedtobe75%intheMMF
plus DZB group, 63% in the MMF alone
group,and71%inthecontrolgroupover
the treatment period based on capsule
counts. Mean MPA trough levels over 24
months were 4.5  3.4 (mcg/ml) and
5.8  4.0 (mcg/ml), respectively, for
MMF plus DZB and MMF alone groups
with expected trough range of 1.0–3.5
g/ml. Treatment was terminated in 23
subjects due to adverse events (5), ele-
vated liver enzymes (2), EBV PCR-
positivity (8), treatment noncompliance
(3), or loss to follow-up (5) (Supplemen-
tal Figure A1).
Table 1—Baseline characteristics of the treatment groups, including all 114 subjects correctly randomized
MMF  DZB MMF alone
Active Control Active Control
n 41 42 31 28
Age (years) 18.3  9.1 18.8  10.5 17.1  6.7 15.8  8.0
Race (% white) 38 (93) 39 (93) 30 (97) 27 (96)
Non-Hispanic (%) 40 (98) 39 (93) 29 (94) 26 (93)
Number of Ab (%)
1 1 (2) 3 (7) 4 (13) 1 (4)
2 11 (27) 8 (19) 7 (23) 7 (25)
3 12 (29) 16 (38) 6 (19) 11 (39)
4 17 (41) 15 (36) 14 (45) 9 (32)
Male sex (%) 23 (56) 25 (60) 20 (65) 16 (57)
2-h C-peptide AUC means (pmol/ml) 0.71  0.36 0.71  0.34 0.65  0.28 0.73  0.36
Baseline A1C (%) 7.5  1.3 7.7  1.6 7.4  1.0 7.5  1.5
Baseline total insulin dose/kg 0.40  0.26 0.36  0.20 0.35  0.15 0.39  0.22
Weight (kg) 58.9  16.6 59.0  16.3 61.3  18.3 57.2  16.7
Height (cm) 162.4  13.5 162.7  13.7 164.4  15.4 160.9  13.4
BMI (kg/m
2) 22.0  4.2 21.8  3.6 22.1  4.1 21.6  4.0
zBMI (only on subjects 20 years) 0.44  1.11 0.66  0.79 0.42  1.02 0.57  0.74
n 30 28 21 23
Mean A1C over 24 months (%) 7.2  1.2 7.2  1.0 7.0  1.2 7.3  0.9
Mean insulin dose/kg over 24 months 0.56  0.29 0.55  0.32 0.59  0.31 0.63  0.34
Mean MPA level over 24 months (mcg/ml)* 4.5  3.4 0.6  0.6 5.8  4.0 0.6  0.2
Received 2 full DZB infusions (%) 40 (98)** 42 (100) 31 (100) 28 (100)
% of subjects MMF compliant*** 36 (88) 41 (98) 27 (87) 27 (96)
Means  SD are presented for continuous variables. *Limit of quantitation 	 0.5 units. **One subject did not receive the second infusion due to patient decision
to continue study treatment. ***80% or greater by capsule count up through last recorded visit starting with month 3.
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MeanAUCC-peptideatentrywas0.70
0.33 pmol/ml. Control subjects lost C-
peptide at a rate of 53.5% per year, and
both the MMF alone and the MMF plus
DZB treatment groups had comparable
rates of loss, 46.4% and 48.1%, respec-
tively. In the primary analysis (Fig. 1A)a t
2 years,;the geometric mean stimulated
C-peptide AUC was 0.28 pmol/ml (95%
CI0.19–0.37)inthosetreatedwithMMF
plus DZB, compared with 0.27 (0.18–
0.37) for their control subjects, P 	 0.47;
and 0.25 (0.14–0.37) in MMF alone
treated subjects, compared with 0.23
(0.12–0.35) for their control subjects,
P 	 0.41. There was no statistical differ-
ence between treatment and control sub-
jectsover2yearsorduringtheearlyphase
when DZB would have been more active.
Results were similar for 4-h AUC mean
C-peptide at 2 years.
During follow-up, all but eight sub-
jects had detectable levels of C-peptide.
The AUC mean C-peptide fell below 0.2
pmol/ml during follow-up in 12 MMF
plus DZB, 16 MMF alone, and 17 control
subjects. Cumulative incidence of decline
of peak C-peptide below 0.2 pmol/ml did
not differ between groups (Fig. 1B).
Intheprimaryanalysis,thegeometric
meanratioforMMFplusDZBversuscon-
trol subjects was 1.02 (95% CI 0.65–
1.59) and for MMF alone versus control
subjects was 1.08 (0.57–2.02). Figure 1C
and D show that these mean ratios and
conﬁdence limits within subgroups, de-
ﬁned by baseline characteristics, are not
nominally signiﬁcantly different from 1,
with the exception of the effect of MMF
alonewithinthe10subjectsinthehighest
tertile of baseline A1C (P 	 0.042). How-
Figure1—EffectofMMFandMMFplusDZBonC-peptideover2years.A)Thegeometricmeansand95%CIsforthe2-hAUCstimulatedC-peptide
levelsovertimewithineachgroup.B)ThecumulativeincidenceofdeclineinpeakC-peptideto0.2pmol/mlwithineachgroup.Therelativehazard
was 0.61 (95% CI: 0.28–1.33, P 	 0.11) for MMF plus DZB vs. control, and 1.05 (0.50–2.19, P 	 0.83) for MMF alone vs. control. C) Ratio of
geometric means for MMF plus DZB vs. control groups, with 95% CIs, within subgroups of subjects deﬁned at baseline. D) Likewise for MMF alone
vs. control (A1C 2nd tertile upper 95% conﬁdence limit is 28.9).
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tertiles, and among all other subgroups,
failedtoreachsigniﬁcancedemonstrating
that variation among subgroups was
withintherealmofchance.Similarresults
applied to subgroups deﬁned from the
mean levels of A1C and insulin dose over
24 months.
DZB reduced CD4CD25 T-cell levels
maximally at 4 weeks (depletion 83.9%
and blocking 97.5%) and these recovered
within 6–12 months. The month 24 C-
peptide level was not associated with ei-
ther percent reduction in CD4CD25
T-cells within the MMF plus DZB group,
or MMF trough levels in either the MMF
plus DZB or MMF alone groups.
A1C and insulin dose
All groups achieved A1C of 7.2–7.3%
throughoutthestudy(Fig.2A).Mirroring
changes in C-peptide, daily insulin dose
slowly rose from below 0.5 units/kg at
baseline to 0.57 units/kg with MMF plus
DZB versus 0.61 units/kg among control
subjects (P 	 0.17); and to 0.65 units/kg
with MMF alone versus 0.62 units/kg
among control subjects (P 	 0.68) (Fig.
2B).
Adverse events
There were 19 serious adverse events
(AEs) reported for 14 subjects (34%) in
theMMFandDZBgroup,nineinﬁvesub-
jects (16%) in the MMF alone group, and
three in three subjects (7%) in the control
group (online appendix Table 1), P 
0.01.
More grade 2 or higher AEs occurred
in MMF plus DZB subjects (167 or 4.1
events/subject) compared with MMF
alone (117, 3.8 events/subject) or control
subjects (133, 3.2 events/subject), P 	
0.09 (online appendix Table 1). Contrary
toexpectations,therewasnodifferencein
the occurrence of infectious or gastroin-
testinal events among groups. Eight indi-
viduals had asymptomatic reactivation of
previous EBV infection using a sensitive
PCR assay (ﬁve in MMF plus DZB, one in
MMF, and two in control). Neutropenia
and leukopenia, both side effects of MMF
andDZB,occurredapproximatelyequally
amongthethreegroups.Aslightexcessof
elevated liver enzymes occurred in the
MMF plus DZB group. Major hypoglyce-
mic events were reported for 27 subjects,
with an average of two each, with no dif-
ference among groups.
CONCLUSIONS— The aim of the
presentstudywastoarrest-celldestruc-
tion in recently diagnosed type 1 diabetic
subjects when preservation of existing
-cells may have a clinically meaningful
effect on long-term outcomes of type 1
diabetes. We found no treatment beneﬁt
from either MMF alone or from the com-
bination of MMF and DZB in this ran-
domized, masked, placebo-controlled
trial.
Although MMF has been effective in
combination with other anti-rejection
drugs (such as sirolimus and tacrolimus)
in a number of transplant protocols (11),
alone it may not have as much effect on
effector cells, which can damage and kill
islets without requiring cell division, the
primary mode of MMF action. Although
several studies have reported a potential
negative effect of MMF on islet cell func-
tion, we did not see any greater loss of
C-peptide in the MMF alone group com-
pared with control subjects. For both
MMF and DZB, we chose the lowest
known effective doses of each. DZB has
beenshowntoreducerecurrencesinmul-
tiple sclerosis (15) and uveitis (16) when
given monthly. Our use of two doses of
DZBmaynothavebeensufﬁcienttoaffect
activated effectors cells in the pancreas
even with MMF, despite reasonably good
depletion/coating in the peripheral circu-
lation. Cyclosporine, which also affects
the IL-2 signaling pathway, was shown to
be effective in past trials if given at high
doses and early enough in the course of
disease (22). This, and the aforemen-
tioned effect of DZB in two other autoim-
mune diseases, suggests that the lower
dose may have played a major part in the
lack of effect of this therapy. Although
higherdosesmayhavegreatertherapeutic
effect, this has to be measured against the
increased risk of side effects. Even at the
doses used in this study, there was an in-
crease in AEs when the two drugs were
used together in comparison to MMF
alone or placebo.
CD4CD25 regulatory T-cells play
an important role in immune regulation
and a potential problem with an anti-IL-2
receptor antibody is worsening autoim-
munity rather than reducing it if the ef-
Figure2—EffectofMMFandMMFplusDZBonglycemiccontrolovertime.A)MeanA1C(%)and95%conﬁdencelimitsovertime.B)Meaninsulin
dose and 95% conﬁdence limits over time within each group.
MMF and DZB in new-onset type 1 diabetes
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population outweigh its effects on the ac-
tivated-effector cell population. In this
study we saw no worsening of -cell de-
struction or development of other auto-
immune conditions with the use of DZB.
While overall compliance with the
MMF and DZB regimens was high, it is
possible that the need to withdraw study
drug, primarily MMF, for various inter-
vals due to AEs, may have affected the
ability to demonstrate a beneﬁcial effect.
However, mechanistic assessments
showed that MMF and DZB each were
bioavailable and had the intended immu-
nologic effects, but these effects were not
associated with the C-peptide levels after
2 years. Modiﬁed anti-CD3 antibodies
havebeenshowntoreducetherateofloss
of C-peptide in new-onset type 1 diabetic
subjects similar to those studied in this
trial (2–4). MMF and anti-IL-2R are
downstream of the important major his-
tocompatibility complex-peptide/T-cell–
receptorinteraction,whichisthedriverof
the autoimmune response. Therapies
such as anti-CD3 and anti-CD20 as well
asantigenssuchasGAD,oralinsulin,and
DiaPep277mayhavethepotentialtoalter
this critical reaction and blunt the direct
activation of autoreactive T-cells rather
than limit their activity and division,
which is where MMF and DZB are most
critical. One additional difference be-
tween this study and the cyclosporine tri-
als (22) that had been successful was that
the time to treatment was 56 days with
anti-CD3 versus 76 days in this study.
Post hoc analysis did not reveal this to be
a factor in the failure to see an effect and
probably suggests that more targeted
therapy at sufﬁcient dose is necessary to
arrest the diabetes process. New thera-
piessuchasDiaPep277inadults(23)or
GAD immunization (24) have recently
been shown to slow the rate of loss of
C-peptide, and others are under study
such as anti-CD20, abatacept, and
thymoglobulin.
Although we were concerned with
the number of adverse events that might
occur from the use of immunosuppres-
sive agents, it is clear from our analysis
that the number and type we detected
were for the most part within our pre-
study expectations and did not prevent
study subjects from continuing treat-
ment. The ﬁnding of asymptomatic low-
level PCR reactivation of EBV in both
treated and untreated patients was unex-
pected and may reﬂect the differential
sensitivity of our EBV viral PCR assay as
well as our rigorous screening program to
ensure patient safety.
Type 1 Diabetes TrialNet is an Na-
tional Institutes of Health (NIH)-
sponsoredmulticentertrialgroupformed
to perform intervention trials in new-
onset type 1 diabetes and pre-diabetes, as
well as to develop immunologic and
mechanistic assays to better understand
type 1 diabetes pathogenesis. There are
several advantages of multicenter net-
works. These include consistency in
study design and study outcomes allow-
ing better comparisons between trials.
Proposed studies are rigorously reviewed
forscientiﬁcandethicaljustiﬁcation,clin-
ical feasibility and prioritization by a di-
verse group of clinicians, basic scientists,
statisticians, and ethicists (25). Trials are
monitored by metabolic, infectious dis-
ease,andsafetymonitoringcommitteesin
addition to oversight by an independent
DSMB.
Although this trial was unsuccessful
atﬁndingnewtherapiestoinduceclinical
remission in type 1 diabetes, it showed
that our network can successfully design,
recruit, and conduct clinical trials of suf-
ﬁcient size. The use of novel agents, alone
or in combination, will be facilitated by
theclinicaltrialprocessdevelopedforthis
ﬁrst trial under the TrialNet mechanism.
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